Biotech Values

[pcrutch]

I agree it's difficult to compare across studies, but I still am having a hard time reconciling the data as better than current options. This comes from their(Merrimack) Phase 2 paper.

"Results from one of the largest studies conducted to date for the second-line treatment of APC (CONKO-003) randomised 165 patients to receive a weekly regimen called OFF or 5-FU/folinic acid alone (Pelzer et al, 2008). Patients receiving the oxaliplatin-containing combination demonstrated significantly improved outcomes in terms of both progression-free survival (13 vs 9 weeks, P=0.012) and overall survival (26 vs 13 weeks, P=0.014), leading to the adoption of this regimen (or slight variations thereof) as a de facto standard of care in the salvage setting."

http://www.ejcancer.com/article/S0959-8049(11)00260-7/abstract